METASTATIC COLORECTAL CANCER (MCRC)
Clinical trials for METASTATIC COLORECTAL CANCER (MCRC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL CANCER (MCRC) trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL CANCER (MCRC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to tackle Hard-to-Treat colorectal cancer
Disease control Not yet recruitingThis study tests a new oral drug, LPM6690176, added to standard chemotherapy and bevacizumab for people with a specific type of advanced colorectal cancer (RAS mutation). The first part finds the safest dose, and the second part compares the new combo against standard treatment a…
Matched conditions: METASTATIC COLORECTAL CANCER (MCRC)
Phase: PHASE1, PHASE2 • Sponsor: Luye Pharma Group Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising drug duo targets Hard-to-Treat HER2 cancers
Disease control Not yet recruitingThis study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…
Matched conditions: METASTATIC COLORECTAL CANCER (MCRC)
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC